FG Onco Lapatinib
Pharmacogenetics of lapatinib treatment
Lapatinib is a medicine used in chemotherapy for breast cancer and other solid tumors. It belongs to the group of kinase inhibitor drugs, which act by blocking the action of the abnormal protein that indicates to the tumor cells that they must multiply. Several scientific studies have shown that different HLA polymorphisms within the major histocompatibility complex (MHC) are strongly associated with the hepatotoxicity of lapatinib treatment. This hepatotoxicity may appear within a few days or several months after initiation of treatment.
The genetic profile FG – Onco Lapatinib evaluates whether the patient is a carrier of the HLA DQA1*02:01 and DRB1*07:01 alleles. The objective of the test is to identify those patients with an increased risk of developing serious side effects, and especially hepatotoxicity, on treatment with lapatinib.
• Patients on pharmacological treatment who wish to customize medication based on their genetic profile
• Patients in whom pharmacological treatments do not show the expected results
Next Generation Sequencing (NGS)
• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Detailed report including, in addition to the type of metabolism of each enzyme, which drugs can generate toxic effects and adverse reactions, as well as dose recommendations.
•Information provided by the analysis allows the selection of the most appropriate drug, and determines the most appropriate dose for each patient.
• Genetic counseling available at no additional cost according to the needs of each client.
DOCUMENTATION – Available on Extranet for clients:
• Informed Consent
• Clinical Questionnaire
• Fasting is not necessary for the test.